2In the first three quarters of 018, the proportion of the top ten batches of vaccine products issued in China exceeded 88%. In the following, the Prospective Industry Research Institute will interpret the first three quarters of China's vaccine industry from the perspective of subdivided products.
Prior to this incident (July 2018), Changchun Changsheng ranked third in the domestic rabies vaccine supplier. Even if it was issued for three consecutive months from July to September, it was 0, and the ranking in the first three quarters still ranked fourth in the country. It can be seen that its position in the domestic rabies vaccine market is precisely because of its large share in the market, this event will cause widespread panic and anger among the public.
Judging from the situation of hepatitis B vaccine enterprises, there were a total of 5 manufacturers in China's hepatitis B vaccine market in the first three quarters, of which Kangtai Biotech and Hanxin Biotech had relatively large batches of issuance, accounting for 44% and 34%, respectively; 3 The companies are Jintan Biotechnology, Hualan Biotechnology and foreign-funded companies GlaxoSmithKline, accounting for 15%, 4% and 3% respectively.
Judging from the situation of the 100, 100, white, and broken vaccine companies in the first three quarters, there are three manufacturing companies, of which Wuhan Biotech's batch issuance accounted for 94%, occupying an absolute market advantage.
Judging from the batch issuance volume of the subdivided products, the current mainstream market is the adsorption of cell-free Baibai combined vaccine, accounting for 83% in the first three quarters of 2018.